Empagliflozin in Patients With Cirrhosis and Ascites

Summary

A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.

Timeline

Start

2023-09-11

Primary completion

2026-06-01

Completion

2026-06-01

Drugs

Indications